Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: Pathologic response correlates with five-year overall survival

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 723-732

  Adams, Sylvia ^a   Chakravarthy, A Bapsi ^b   Donach, Martin ^a   Spicer, Darcy ^c   Lymberis, Stella ^a   Singh, Baljit ^a   Bauer, Joshua A ^b   Hochman, Tsivia ^a   Goldberg, Judith D ^a   Muggia, Franco ^a   Schneider, Robert J ^a   Pietenpol, Jennifer A ^b   Formenti, Silvia C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Concurrent chemoradiation; Locally advanced breast cancer; Neoadjuvant; Pathologic response; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CAUCASIAN; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISPANIC; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RACE DIFFERENCE; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78649288957     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1181-8     Document Type: Article

References (57)

1. LD Feldman GN Hortobagyi AU Buzdar FC Ames GR Blumenschein 1986 Pathological assessment of response to induction chemotherapy in breast cancer Cancer Res 46 5 2578 2581 3697997
2. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn VG Vogel SR Dakhil D Tamkus KM King ER Pajon MJ Wright J Robert S Paik EP Mamounas N Wolmark 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols -18 and b-27 J Clin Oncol 26 5 778 785 10.1200/JCO.2007.15.0235 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
3. AU Buzdar NK Ibrahim D Francis DJ Booser ES Thomas RL Theriault L Pusztai MC Green BK Arun SH Giordano M Cristofanilli DK Frye TL Smith KK Hunt SE Singletary AA Sahin MS Ewer TA Buchholz D Berry GN Hortobagyi 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 16 3676 3685 10.1200/JCO.2005.07.032 10.1200/JCO.2005.07. 032 15738535
4. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233. doi: 10.1158/1078-0432.CCR-06-1345 (Pubitemid 46121873)
5. WM Sikov DS Dizon R Strenger RD Legare KP Theall TA Graves JS Gass TA Kennedy MA Fenton 2009 Frequent pathologic complete responses in aggressive stages ii to iii breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a brown university oncology group study J Clin Oncol 27 28 4693 4700 10.1200/JCO.2008.21.4163 10.1200/JCO.2008.21.4163 19720916
6. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with her2-positive locally advanced breast cancer (the noah trial): a randomised controlled superiority trial with a parallel her2-negative cohort. Lancet 375(9712):377-384. doi: 10.1016/S0140-6736(09)61964-4
7. S Chua IE Smith RP A'Hern GA Coombes TF Hickish AC Robinson RW Laing ME O'Brien SR Ebbs A Hong A Wardley T Mughal M Verrill D Dubois JM Bliss 2005 Neoadjuvant vinorelbine/epirubicin (ve) versus standard adriamycin/ cyclophosphamide (ac) in operable breast cancer: analysis of response and tolerability in a randomised phase iii trial (topic 2) Ann Oncol 16 9 1435 1441 10.1093/annonc/mdi276 10.1093/annonc/mdi276 15946977 (Pubitemid 41222415)
8. AU Buzdar SE Singletary RL Theriault DJ Booser V Valero N Ibrahim TL Smith L Asmar D Frye N Manuel SW Kau M McNeese E Strom K Hunt F Ames GN Hortobagyi 1999 Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer J Clin Oncol 17 11 3412 3417 10550135
9. TR Evans A Yellowlees E Foster H Earl DA Cameron AW Hutcheon RE Coleman T Perren CJ Gallagher M Quigley J Crown AL Jones M Highley RC Leonard JL Mansi 2005 Phase iii randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study J Clin Oncol 23 13 2988 2995 10.1200/JCO.2005.06.156 10.1200/JCO.2005.06.156 15860854 (Pubitemid 46224118)
10. JA Low AW Berman SM Steinberg DN Danforth ME Lippman SM Swain 2004 Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy J Clin Oncol 22 20 4067 4074 10.1200/JCO.2004.04.068 10.1200/JCO.2004.04.068 15483018 (Pubitemid 41185175)
11. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert AK Ah-See O Eremin LG Walker TK Sarkar SP Eggleton KN Ogston 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 6 1456 1466 10.1200/JCO.20.6.1456 11896092 (Pubitemid 34260523)
12. WJ Gradishar SB Wedam M Jahanzeb J Erban SA Limentani KT Tsai SR Olsen SM Swain 2005 Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage iii breast cancer Ann Oncol 16 8 1297 1304 10.1093/annonc/mdi254 10.1093/annonc/mdi254 15905305 (Pubitemid 41158474)
13. G von Minckwitz S Kummel P Vogel C Hanusch H Eidtmann J Hilfrich B Gerber J Huober SD Costa C Jackisch S Loibl K Mehta M Kaufmann 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase iii randomized gepartrio trial J Natl Cancer Inst 100 8 542 551 10.1093/jnci/djn085 10.1093/jnci/djn085
14. G von Minckwitz G Raab A Caputo M Schutte J Hilfrich JU Blohmer B Gerber SD Costa E Merkle H Eidtmann D Lampe C Jackisch A du Bois M Kaufmann 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the Geparduo study of the German Breast Group J Clin Oncol 23 12 2676 2685 10.1200/JCO.2005.05.078 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
15. HJ Burstein LN Harris R Gelman SC Lester RA Nunes CM Kaelin LM Parker LW Ellisen I Kuter MA Gadd RL Christian PR Kennedy VF Borges CA Bunnell J Younger BL Smith EP Winer 2003 Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for her2 overexpressing stage ii or iii breast cancer: a pilot study J Clin Oncol 21 1 46 53 10.1200/JCO.2003.03.124 12506169
16. MC Green AU Buzdar T Smith NK Ibrahim V Valero MF Rosales M Cristofanilli DJ Booser L Pusztai E Rivera RL Theriault C Carter D Frye KK Hunt WF Symmans EA Strom AA Sahin W Sikov GN Hortobagyi 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 25 5983 5992 10.1200/JCO.2005.06.232 10.1200/JCO.2005.06.232 16087943
17. V Guarneri K Broglio SW Kau M Cristofanilli AU Buzdar V Valero T Buchholz F Meric L Middleton GN Hortobagyi AM Gonzalez-Angulo 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 7 1037 1044 10.1200/JCO.2005.02.6914 10.1200/JCO.2005.02.6914 16505422 (Pubitemid 46638799)
18. M Colleoni F Nole I Minchella C Noberasco A Luini R Orecchia P Veronesi S Zurrida G Viale A Goldhirsch 1998 Pre-operative chemotherapy and radiotherapy in breast cancer Eur J Cancer 34 5 641 645 10.1016/S0959-8049(97)10091-0 9713267 (Pubitemid 28218937)
19. V Lorvidhaya I Chitapanarux S Sangruchi P Lertsanguansinchai Y Kongthanarat S Tangkaratt E Visetsiri 2003 Concurrent mitomycin c, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial Int j Radiat Oncol Biol Phys 55 5 1226 1232 12654431
20. P Zatloukal L Petruzelka M Zemanova L Havel F Janku L Judas A Kubik E Krepela P Fiala L Pecen 2004 Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer 46 1 87 98 10.1016/j.lungcan.2004.03.004 10.1016/j.lungcan.2004.03.004 15364136 (Pubitemid 39201387)
21. M Takada M Fukuoka M Kawahara T Sugiura A Yokoyama S Yokota Y Nishiwaki K Watanabe K Noda T Tamura H Fukuda N Saijo 2002 Phase iii study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin, etoposide for limited-stage small-cell lung cancer: results of the japan clinical oncology group study 9104 J Clin Oncol 20 14 3054 3060 10.1200/JCO.2002.12.071 12118018 (Pubitemid 34791094)
22. K Furuse M Fukuoka M Kawahara H Nishikawa Y Takada S Kudoh N Katagami Y Ariyoshi 1999 Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 9 2692 2699 10561343
23. DL Kwong JS Sham GK Au DT Chua PW Kwong AC Cheng PM Wu MW Law CC Kwok CC Yau KY Wan RT Chan DD Choy 2004 Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study J Clin Oncol 22 13 2643 2653 10.1200/JCO.2004.05.173 10.1200/JCO.2004.05.173 15226332 (Pubitemid 41103752)
24. SC Formenti M Volm KA Skinner D Spicer D Cohen E Perez AC Bettini S Groshen C Gee B Florentine M Press P Danenberg F Muggia 2003 Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial J Clin Oncol 21 5 864 870 10.1200/JCO.2003.06.132 12610186 (Pubitemid 46606446)
25. AB Chakravarthy MC Kelley B McLaren CI Truica D Billheimer IA Mayer AM Grau DH Johnson JF Simpson RD Beauchamp C Jones JA Pietenpol 2006 Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer Clin Cancer Res 12 5 1570 1576 10.1158/1078-0432.CCR-05-2304 10.1158/1078-0432.CCR-05-2304 16533783
26. SC Formenti G Dunnington B Uzieli H Lenz S Keren-Rosenberg H Silberman D Spicer M Denk G Leichman S Groshen K Watkins F Muggia B Florentine M Press K Danenberg P Danenberg 1997 Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy Int J Radiat Oncol Biol Phys 39 5 1059 1068 9392545
27. LE Morrell YJ Lee J Hurley M Arias C Mies SP Richman H Fernandez KA Donofrio WA Raub Jr PA Cassileth 1998 A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma Cancer 82 3 503 511 10.1002/(SICI)1097-0142(19980201)82:3<503::AID-CNCR12>3.0.CO;2-5 10.1002/(SICI)1097-0142(19980201)82:3<503::AID-CNCR12>3.0.CO;2-5 9452268 (Pubitemid 28112989)
28. R Yerushalmi MM Hayes KA Gelmon S Chia C Bajdik B Norris C Speers P Hassell SE O'Reilly S Allan TN Shenkier 2009 A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers Clin Breast Cancer 9 3 166 172 10.3816/CBC.2009.n.027 10.3816/CBC.2009.n.027 19661040
29. YW Moon SY Rha HC Jeung WI Yang CO Suh HC Chung 2005 Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (ifac) in locally advanced breast cancer: an early response predicts good prognosis Ann Oncol 16 11 1778 1785 10.1093/annonc/mdi360 10.1093/annonc/mdi360 16091429 (Pubitemid 41631240)
30. GF Schwartz CA Birchansky LT Komarnicky CM Mansfield RI Cantor WA Biermann FM Fellin J McFarlane 1994 Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast Cancer 73 2 362 369 10.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L 8293401
31. M Zambetti S Oriana P Quattrone P Verderio M Terenziani R Zucali P Valagussa G Bonadonna 1999 Combined sequential approach in locally advanced breast cancer Ann Oncol 10 3 305 310 10.1023/A:1008345901178 10355574 (Pubitemid 29217221)
32. Frasci G, D'Aiuto G, Comella P, D'Aiuto M, Di Bonito M, Ruffolo P, Iodice G, Petrillo A, Lastoria S, Oliviero P, Capasso I, Montella M, Siani C, Santangelo M, Vizioli L, Comella G (2009) Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol. doi: 10.1093/annonc/mdp356
33. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V (2010) Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: long-term results from the University of Texas M. D. Anderson Cancer Center Study id97-099. Cancer 116(5):1210-1217. doi: 10.1002/cncr.24901
34. AA Ezzat EM Ibrahim DS Ajarim MM Rahal MA Raja AM Tulbah OA Al-Malik M Al-Shabanah R Sorbris 2004 Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients Br J Cancer 90 5 968 974 10.1038/sj.bjc.6601616 10.1038/sj.bjc.6601616 14997191 (Pubitemid 38495813)
35. LA Carey R Metzger EC Dees F Collichio CI Sartor DW Ollila N Klauber-DeMore J Halle L Sawyer DT Moore ML Graham 2005 American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 15 1137 1142 10.1093/jnci/dji206 10.1093/jnci/dji206 16077072 (Pubitemid 41511213)
36. G Bonadonna P Valagussa C Brambilla L Ferrari A Moliterni M Terenziani M Zambetti 1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 1 93 100 9440728
37. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham M Begovic A DeCillis A Robidoux RG Margolese AB Cruz Jr JL Hoehn AW Lees NV Dimitrov HD Bear 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 2672 2685 9704717
38. WF Symmans F Peintinger C Hatzis R Rajan H Kuerer V Valero L Assad A Poniecka B Hennessy M Green AU Buzdar SE Singletary GN Hortobagyi L Pusztai 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 28 4414 4422 10.1200/JCO.2007.10.6823 10.1200/JCO.2007.10.6823 17785706 (Pubitemid 350013847)
39. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra RL Theriault G Singh SM Binkley N Sneige TA Buchholz MI Ross MD McNeese AU Buzdar GN Hortobagyi SE Singletary 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 460 469 10080586
40. WG Cance LA Carey BF Calvo C Sartor L Sawyer DT Moore J Rosenman DW Ollila M Graham 2nd 2002 Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival Ann Surg 236 3 295 302 10.1097/01.SLA.0000027526.67560.64 10.1097/00000658-200209000-00006 12192316 discussion 302-303
41. AJCC cancer staging manual (2010). 7th edn. Springer
42. V Shanta R Swaminathan R Rama R Radhika 2008 Retrospective analysis of locally advanced noninflammatory breast cancer from chennai, South India, 1990-1999 Int J Radiat Oncol Biol Phys 70 1 51 58 10.1016/j.ijrobp.2007.05.050 17869447 (Pubitemid 350258595)
43. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 8 2329 2334 10.1158/1078-0432.CCR-06-1109 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
44. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia WF Symmans AM Gonzalez-Angulo B Hennessy M Green M Cristofanilli GN Hortobagyi L Pusztai 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 1275 1281 10.1200/JCO.2007.14. 4147 10.1200/JCO.2007.14.4147 18250347
45. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 5678 5685 10.1158/1078-0432.CCR- 04-2421 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
46. MY Kim T Oskarsson S Acharyya DX Nguyen XH Zhang L Norton J Massague 2009 Tumor self-seeding by circulating cancer cells Cell 139 7 1315 1326 10.1016/j.cell.2009.11.025 10.1016/j.cell.2009.11.025 20064377
47. CJ Creighton X Li M Landis JM Dixon VM Neumeister A Sjolund DL Rimm H Wong A Rodriguez JI Herschkowitz C Fan X Zhang X He A Pavlick MC Gutierrez L Renshaw AA Larionov D Faratian SG Hilsenbeck CM Perou MT Lewis JM Rosen JC Chang 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci USA 106 33 13820 13825 10.1073/pnas.0905718106 10.1073/pnas.0905718106 19666588
48. F Yu H Yao P Zhu X Zhang Q Pan C Gong Y Huang X Hu F Su J Lieberman E Song 2007 Let-7 regulates self renewal and tumorigenicity of breast cancer cells Cell 131 6 1109 1123 10.1016/j.cell.2007.10.054 10.1016/j.cell.2007.10.054 18083101 (Pubitemid 350235025)
49. JA Bauer AB Chakravarthy JM Rosenbluth D Mi EH Seeley N De Matos Granja-Ingram MG Olivares MC Kelley IA Mayer IM Meszoely JA Means-Powell KN Johnson CJ Tsai GD Ayers ME Sanders RJ Schneider SC Formenti RM Caprioli JA Pietenpol 2010 Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation Clin Cancer Res 16 2 681 690 10.1158/1078-0432.CCR-09- 1091 10.1158/1078-0432.CCR-09-1091 20068102
50. K Nishio H Arioka T Ishida H Fukumoto H Kurokawa M Sata M Ohata N Saijo 1995 Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of map kinase and cdc2 kinase by paclitaxel Int J Cancer 63 5 688 693 10.1002/ijc.2910630514 7591286
51. T Ganz 2003 Defensins: antimicrobial peptides of innate immunity Nat Rev Immunol 3 9 710 720 10.1038/nri1180 10.1038/nri1180 12949495 (Pubitemid 41070812)
52. B Kreike M van Kouwenhove H Horlings B Weigelt H Peterse H Bartelink MJ van de Vijver 2007 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 5 R65 10.1186/bcr1771 10.1186/bcr1771 17910759 (Pubitemid 350187481)
53. L Apetoh F Ghiringhelli A Tesniere M Obeid C Ortiz A Criollo G Mignot MC Maiuri E Ullrich P Saulnier H Yang S Amigorena B Ryffel FJ Barrat P Saftig F Levi R Lidereau C Nogues JP Mira A Chompret V Joulin F Clavel-Chapelon J Bourhis F Andre S Delaloge T Tursz G Kroemer L Zitvogel 2007 Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 9 1050 1059 10.1038/nm1622 10.1038/nm1622 17704786 (Pubitemid 47517504)
54. SC Formenti S Demaria 2009 Systemic effects of local radiotherapy Lancet Oncol 10 7 718 726 10.1016/S1470-2045(09)70082-8 10.1016/S1470-2045(09)70082-8 19573801
55. SC Formenti S Demaria 2008 Effects of chemoradiation on tumor-host interactions: the immunologic side J Clin Oncol 26 9 1562 1563 10.1200/JCO.2007.15.5499 10.1200/JCO.2007.15.5499 18349411 author reply 1563
56. SC Formenti 2010 Immunological aspects of local radiotherapy: clinical relevance Discov Med 9 45 119 124 20193637
57. Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD (2010) Paclitaxel enhances early dendritic cell maturation and function through tlr4 signaling in mice. Cell Immunol. doi: 10.1016/j.cellimm.2010.03.001